Perseus Proteomics, Inc. (JP:4882) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Perseus Proteomics, Inc. has announced the publication of an abstract for its radiopharmaceutical therapy, PPMX-T002, aimed at treating solid cancers, at the EANM ’24 Annual Congress. PPMX-T002 targets the cadherin 3 protein on various solid tumors and has shown enhanced efficacy in preclinical trials when using Actinium 225 compared to Yttrium 90.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.